Stoke Therapeutics (STOK) EBT Margin Growth (1y) (2023 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) EBT Margin Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -392.00 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 29,565.00 |
| 10 | Stoke Therapeutics | 1.96 Bn | 1.66 Bn | - | -49,083.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49,083.00 |
| Mar 31, 2026 | -87,474.00 |
| Dec 31, 2025 | -407,715.00 |
| Sep 30, 2025 | 16,735.00 |
| Jun 30, 2025 | 36,192.00 |
| Mar 31, 2025 | 69,756.00 |
| Dec 31, 2024 | 91,632.00 |
| Sep 30, 2024 | 20,309.00 |
| Jun 30, 2024 | 79,996.00 |
| Mar 31, 2024 | -15,754.00 |
| Dec 31, 2023 | -17,724.00 |
| Sep 30, 2023 | 15,714.00 |
| Jun 30, 2023 | -53,240.00 |
| Mar 31, 2023 | 37,567.00 |